Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 4Lymphoma, B-Cell 3Lymphoma 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Hematologic Neoplasms 1Disease Progression 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

siltuximab 4fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2tocilizumab 1talquetamab 1axicabtagene ciloleucel 1Neuropsychological Tests 1Metoprolol 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Infliximab 1Etanercept 1Dexamethasone 1Contrast Media 1Calcium Dobesilate 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cytokine Release Syndrome × axicabtagene ciloleucel × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡